End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,090 IDR | +0.46% | -6.03% | -26.85% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The firm trades with high earnings multiples: 28.52 times its 2024 earnings per share.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.85% | 993M | - | ||
-14.92% | 84.68B | B- | ||
+13.30% | 81.12B | C+ | ||
+11.62% | 29.59B | C+ | ||
-12.71% | 16.73B | B | ||
-2.28% | 16.36B | A- | ||
-2.63% | 14.92B | A- | ||
-31.58% | 11.77B | - | - | |
-0.08% | 11.72B | A- | ||
+27.44% | 11.71B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- HEAL Stock
- Ratings PT Medikaloka Hermina Tbk